Alzinova: Diagnostics collaboration with Fujirebio - Redeye

Redeye comments on today’s announcement that Alzinova has signed a non-binding Letter of Intent with Fujirebio regarding the potential development and commercialization of the company’s blood-based Alzheimer’s diagnostic program. While the agreement remains contingent on the outcome of the ongoing validation work with Amsterdam UMC, we view the interest from a global leader in neurodegenerative diagnostics as an encouraging external validation of the commercial potential of Alzinova’s Aβ42CC technology beyond its therapeutic applications.

Länk till analysen i sin helhet: https://www.redeye.se/research/1172763/alzinova-diagnostics-collaboration-with-fujirebio?utm_source=finwire&utm_medium=RSS